Symbols / ALMS Stock $24.93 -4.08% Alumis Inc.

Healthcare • Biotechnology • United States • NMS
ALMS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Martin Babler Ph.D.
Exch · Country NMS · United States
Market Cap 3.17B
Enterprise Value 2.90B
Income -243.32M
Sales 24.05M
FCF (ttm) -202.33M
Book/sh 2.88
Cash/sh 2.42
Employees 221
Insider 10d —
IPO Jun 28, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.71
PEG —
P/S 131.85
P/B 8.66
P/C —
EV/EBITDA -6.61
EV/Sales 120.56
Quick Ratio 4.24
Current Ratio 4.34
Debt/Eq 12.25
LT Debt/Eq —
EPS (ttm) -2.86
EPS next Y -3.23
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-03-19
ROA -73.36%
ROE -86.68%
ROIC —
Gross Margin 100.00%
Oper. Margin -50.67%
Profit Margin 0.00%
Shs Outstand 123.14M
Shs Float 84.99M
Insider Own 0.62%
Instit Own 77.10%
Short Float 17.52%
Short Ratio 7.16
Short Interest 12.21M
52W High 30.60
vs 52W High -18.53%
52W Low 2.76
vs 52W Low 803.26%
Beta —
Impl. Vol. 1.03%
Rel Volume 0.85
Avg Volume 1.48M
Volume 1.25M
Target (mean) $38.40
Tgt Median $38.00
Tgt Low $25.00
Tgt High $55.00
# Analysts 10
Recom Strong_buy
Prev Close $25.99
Price $24.93
Change -4.08%
About

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.40
Mean price target
2. Current target
$24.93
Latest analyst target
3. DCF / Fair value
$-29.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.93
Low
$25.00
High
$55.00
Mean
$38.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main Oppenheimer Outperform → Outperform $55
2026-03-30 main Chardan Capital Buy → Buy $38
2026-03-30 main HC Wainwright & Co. Buy → Buy $25
2026-03-20 main Morgan Stanley Overweight → Overweight $38
2026-03-20 main Chardan Capital Buy → Buy $38
2026-03-11 init Raymond James — → Strong Buy $46
2026-02-25 init Stifel — → Buy $44
2026-01-21 init Chardan Capital — → Buy $37
2026-01-09 reit HC Wainwright & Co. Buy → Buy $40
2026-01-07 main Leerink Partners Outperform → Outperform $32
2026-01-07 main Morgan Stanley Overweight → Overweight $33
2026-01-07 main Guggenheim Buy → Buy $32
2026-01-06 main Wells Fargo Overweight → Overweight $39
2025-12-18 main HC Wainwright & Co. Buy → Buy $20
2025-08-15 main Morgan Stanley Overweight → Overweight $22
2025-08-14 reit HC Wainwright & Co. Buy → Buy $14
2025-07-25 init Wells Fargo — → Overweight $17
2025-07-25 reit HC Wainwright & Co. Buy → Buy $14
2025-05-15 main Oppenheimer Outperform → Outperform $25
2025-04-30 reit HC Wainwright & Co. Buy → Buy $14
News
RSS: Latest ALMS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-09 AKKARAJU SRINIVAS Director — 588,235 $17.00 $9,999,995
2026-01-08 TANANBAUM JAMES B Director and Beneficial Owner of more than 10% of a Class of Security — 411,764 $17.00 $6,999,988
2026-01-08 FORESITE CAPITAL MANAGEMENT VI, LLC. Beneficial Owner of more than 10% of a Class of Security — 411,764 $17.00 $6,999,988
2025-12-05 AKKARAJU SRINIVAS Director — 186,377 $8.95 $1,833,760
2025-12-04 AKKARAJU SRINIVAS Director — 262,027 $7.55 $2,039,901
2025-12-01 AKKARAJU SRINIVAS Director — 173,589 $7.46 $1,310,677
2025-11-21 TANANBAUM JAMES B Director and Beneficial Owner of more than 10% of a Class of Security — 72,212 $7.38 $532,925
2025-11-21 FORESITE CAPITAL MANAGEMENT VI, LLC. Beneficial Owner of more than 10% of a Class of Security — 72,212 $7.38 $532,925
2025-11-20 AKKARAJU SRINIVAS Director — 125,743 $7.20 $905,350
2025-11-19 AKKARAJU SRINIVAS Director — 241,338 $5.51 $1,529,865
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
24.05
0.00
0.00
0.00
Operating Revenue
24.05
0.00
0.00
0.00
Operating Expense
477.85
+58.89%
300.75
+90.14%
158.17
+38.93%
113.85
Research And Development
386.00
+45.36%
265.55
+92.88%
137.68
+35.90%
101.30
Selling General And Administration
91.86
+160.95%
35.20
+71.72%
20.50
+63.38%
12.55
General And Administrative Expense
91.86
+160.95%
35.20
+71.72%
20.50
+63.38%
12.55
Other Gand A
91.86
+160.95%
35.20
+71.72%
20.50
+63.38%
12.55
Total Expenses
477.85
+58.89%
300.75
+90.14%
158.17
+38.93%
113.85
Operating Income
-453.80
-50.89%
-300.75
-90.14%
-158.17
-38.93%
-113.85
Total Operating Income As Reported
-453.80
-50.89%
-300.75
-90.14%
-158.17
-38.93%
-113.85
EBITDA
-450.31
-51.31%
-297.60
-89.69%
-156.89
-38.11%
-113.60
Normalized EBITDA
-638.22
-118.42%
-292.20
-86.38%
-156.77
-38.00%
-113.60
Reconciled Depreciation
3.50
+10.91%
3.15
+145.48%
1.28
+413.60%
0.25
EBIT
-453.80
-50.89%
-300.75
-90.14%
-158.17
-38.93%
-113.85
Total Unusual Items
187.91
+3575.90%
-5.41
-4442.86%
-0.12
—
Total Unusual Items Excluding Goodwill
187.91
+3575.90%
-5.41
-4442.86%
-0.12
—
Special Income Charges
187.91
0.00
—
—
Restructuring And Mergern Acquisition
-187.91
0.00
—
—
Net Income
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Pretax Income
-251.89
+14.39%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Net Non Operating Interest Income Expense
14.18
+17.97%
12.02
+256.89%
3.37
+69.08%
1.99
Net Interest Income
14.18
+17.97%
12.02
+256.89%
3.37
+69.08%
1.99
Interest Income Non Operating
14.18
+17.97%
12.02
+256.89%
3.37
+69.08%
1.99
Interest Income
14.18
+17.97%
12.02
+256.89%
3.37
+69.08%
1.99
Other Income Expense
187.74
+3514.04%
-5.50
-2840.64%
-0.19
-159.72%
-0.07
Other Non Operating Income Expenses
-0.17
-81.72%
-0.09
-36.76%
-0.07
+5.56%
-0.07
Gain On Sale Of Security
—
-5.41
-4442.86%
-0.12
—
Tax Provision
-8.56
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
6.39
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Net Income From Continuing Operation Net Minority Interest
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Net Income From Continuing And Discontinued Operation
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Net Income Continuous Operations
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Normalized Income
-424.84
-47.09%
-288.83
-86.49%
-154.87
-38.37%
-111.93
Net Income Common Stockholders
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Diluted EPS
—
-10.38
-247.21%
-2.99
-2.59%
-2.91
Basic EPS
—
-10.38
-247.21%
-2.99
-2.59%
-2.91
Basic Average Shares
—
28.34
-45.33%
51.84
+34.98%
38.41
Diluted Average Shares
—
28.34
-45.33%
51.84
+34.98%
38.41
Diluted NI Availto Com Stockholders
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
411.94
+20.81%
340.99
+280.52%
89.61
-17.15%
108.17
Current Assets
318.23
+3.93%
306.19
+473.85%
53.36
-47.97%
102.56
Cash Cash Equivalents And Short Term Investments
308.50
+7.02%
288.26
+488.87%
48.95
-47.29%
92.86
Cash And Cash Equivalents
89.67
-47.11%
169.53
+268.57%
46.00
+79.60%
25.61
Other Short Term Investments
218.83
+84.30%
118.74
+3916.81%
2.96
-95.60%
67.25
Receivables
2.08
+14.96%
1.81
+150.97%
0.72
+44.40%
0.50
Taxes Receivable
0.74
-33.57%
1.11
+81.43%
0.61
+22.80%
0.50
Accrued Interest Receivable
1.34
+92.41%
0.70
+546.30%
0.11
—
Prepaid Assets
6.42
-58.15%
15.35
+341.76%
3.48
-61.32%
8.98
Restricted Cash
0.08
0.00
-100.00%
0.11
-45.15%
0.21
Other Current Assets
1.14
+49.87%
0.76
+702.11%
0.10
—
Total Non Current Assets
93.71
+169.24%
34.80
-4.00%
36.26
+545.91%
5.61
Net PPE
35.16
+4.36%
33.69
-4.35%
35.22
+687.13%
4.47
Gross PPE
43.15
+12.81%
38.25
+4.41%
36.63
+674.13%
4.73
Accumulated Depreciation
-7.99
-75.29%
-4.56
-223.65%
-1.41
-447.86%
-0.26
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.68
+0.00%
2.68
+0.00%
2.68
+406.62%
0.53
Construction In Progress
—
—
0.00
-100.00%
0.58
Other Properties
22.81
+27.10%
17.95
+9.72%
16.36
+355.20%
3.59
Leases
17.66
+0.21%
17.62
+0.15%
17.59
+56648.39%
0.03
Goodwill And Other Intangible Assets
50.96
0.00
—
—
Other Non Current Assets
7.59
+581.76%
1.11
+7.95%
1.03
-9.40%
1.14
Total Liabilities Net Minority Interest
110.64
+36.79%
80.89
-81.14%
428.87
+41.35%
303.41
Current Liabilities
73.32
+44.01%
50.91
+143.93%
20.87
+56.31%
13.35
Payables And Accrued Expenses
49.37
+18.70%
41.59
+206.56%
13.57
+60.24%
8.47
Payables
10.11
+5.01%
9.62
+760.82%
1.12
-35.00%
1.72
Accounts Payable
10.11
+5.01%
9.62
+760.82%
1.12
-35.00%
1.72
Current Accrued Expenses
39.26
+22.82%
31.96
+156.78%
12.45
+84.52%
6.75
Pensionand Other Post Retirement Benefit Plans Current
17.82
+129.56%
7.76
+39.03%
5.58
+56.18%
3.58
Current Debt And Capital Lease Obligation
4.67
+199.94%
1.56
-9.48%
1.72
+31.30%
1.31
Current Capital Lease Obligation
4.67
+199.94%
1.56
-9.48%
1.72
+31.30%
1.31
Current Deferred Liabilities
1.46
0.00
—
—
Current Deferred Revenue
1.46
0.00
—
—
Total Non Current Liabilities Net Minority Interest
37.33
+24.51%
29.98
-92.65%
408.00
+40.66%
290.06
Long Term Debt And Capital Lease Obligation
32.24
+10.56%
29.16
-5.49%
30.86
+6479.96%
0.47
Long Term Capital Lease Obligation
32.24
+10.56%
29.16
-5.49%
30.86
+6479.96%
0.47
Non Current Deferred Liabilities
4.75
0.00
—
—
Non Current Deferred Revenue
2.61
0.00
—
—
Non Current Deferred Taxes Liabilities
2.14
0.00
—
—
Other Non Current Liabilities
0.33
-59.41%
0.81
-54.09%
1.77
-56.97%
4.12
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
375.37
+31.49%
285.47
Stockholders Equity
301.30
+15.84%
260.10
+176.67%
-339.26
-73.76%
-195.24
Common Stock Equity
301.30
+15.84%
260.10
+176.67%
-339.26
-73.76%
-195.24
Capital Stock
0.01
+100.00%
0.01
+400.00%
0.00
+0.00%
0.00
Common Stock
0.01
+100.00%
0.01
+400.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
104.71
+92.45%
54.41
+4.94%
51.84
+0.00%
51.84
Ordinary Shares Number
104.71
+92.45%
54.41
+4.94%
51.84
+0.00%
51.84
Additional Paid In Capital
1,202.97
+30.96%
918.61
+3566.37%
25.05
+76.33%
14.21
Retained Earnings
-901.88
-36.95%
-658.55
-80.76%
-364.32
-74.04%
-209.32
Gains Losses Not Affecting Retained Earnings
0.19
+370.00%
0.04
+1900.00%
0.00
+101.57%
-0.13
Other Equity Adjustments
0.19
+370.00%
0.04
+1900.00%
0.00
+101.57%
-0.13
Total Equity Gross Minority Interest
301.30
+15.84%
260.10
+176.67%
-339.26
-73.76%
-195.24
Total Capitalization
301.30
+15.84%
260.10
+176.67%
-339.26
-73.76%
-195.24
Working Capital
244.91
-4.06%
255.28
+685.81%
32.49
-63.58%
89.20
Invested Capital
301.30
+15.84%
260.10
+176.67%
-339.26
-73.76%
-195.24
Total Debt
36.91
+20.15%
30.72
-5.70%
32.58
+1731.37%
1.78
Capital Lease Obligations
36.91
+20.15%
30.72
-5.70%
32.58
+1731.37%
1.78
Net Tangible Assets
250.34
-3.75%
260.10
+176.67%
-339.26
-73.76%
-195.24
Tangible Book Value
250.34
-3.75%
260.10
+176.67%
-339.26
-73.76%
-195.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-369.52
-44.87%
-255.08
-96.25%
-129.97
-20.66%
-107.72
Cash Flow From Continuing Operating Activities
-369.52
-44.87%
-255.08
-96.25%
-129.97
-20.66%
-107.72
Net Income From Continuing Operations
-243.32
+17.30%
-294.23
-89.84%
-154.99
-38.47%
-111.93
Depreciation Amortization Depletion
3.50
+10.91%
3.15
+145.48%
1.28
+413.60%
0.25
Depreciation And Amortization
3.50
+10.91%
3.15
+145.48%
1.28
+413.60%
0.25
Other Non Cash Items
-186.21
-310443.33%
0.06
-97.01%
2.01
+111.58%
0.95
Stock Based Compensation
43.52
+123.69%
19.46
+125.59%
8.62
+44.71%
5.96
Asset Impairment Charge
0.53
0.00
-100.00%
0.56
0.00
Operating Gains Losses
—
5.41
+425.34%
1.03
—
Gain Loss On Investment Securities
—
5.41
+4442.86%
0.12
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
-99.45%
0.91
0.00
Change In Working Capital
17.76
+20.30%
14.76
+22.41%
12.06
+729.33%
-1.92
Change In Prepaid Assets
28.70
+310.53%
-13.63
-362.88%
5.19
+162.09%
-8.35
Change In Payables And Accrued Expense
-6.47
-121.40%
30.25
+331.17%
7.02
-3.32%
7.26
Change In Accrued Expense
8.12
-62.64%
21.75
+183.95%
7.66
+28.43%
5.96
Change In Payable
-14.60
-271.61%
8.51
+1424.92%
-0.64
-149.61%
1.29
Change In Account Payable
-6.04
-170.96%
8.51
+1424.92%
-0.64
-149.61%
1.29
Change In Other Working Capital
4.07
—
—
—
Change In Other Current Assets
-5.54
0.00
—
—
Change In Other Current Liabilities
-3.00
-61.73%
-1.86
-1190.28%
-0.14
+82.44%
-0.82
Investing Cash Flow
287.88
+352.99%
-113.79
-288.17%
60.47
+187.96%
-68.75
Cash Flow From Continuing Investing Activities
287.88
+352.99%
-113.79
-288.17%
60.47
+187.96%
-68.75
Net PPE Purchase And Sale
-0.65
+62.30%
-1.73
+61.50%
-4.50
-86.99%
-2.41
Purchase Of PPE
-0.65
+62.30%
-1.73
+61.50%
-4.50
-86.99%
-2.41
Capital Expenditure
-0.65
+62.30%
-1.73
+61.50%
-4.50
-86.99%
-2.41
Net Investment Purchase And Sale
238.79
+313.09%
-112.06
-272.47%
64.97
+197.93%
-66.34
Purchase Of Investment
-209.17
+12.87%
-240.06
-2028.36%
-11.28
+94.61%
-209.07
Sale Of Investment
447.95
+249.96%
128.00
+67.87%
76.25
-46.58%
142.73
Net Other Investing Changes
49.74
—
—
—
Financing Cash Flow
2.07
-99.58%
492.37
+449.01%
89.68
-11.75%
101.63
Cash Flow From Continuing Financing Activities
2.07
-99.58%
492.37
+449.01%
89.68
-11.75%
101.63
Net Common Stock Issuance
0.00
-100.00%
193.32
0.00
—
Common Stock Payments
—
—
0.00
—
Repurchase Of Capital Stock
—
—
0.00
—
Proceeds From Stock Option Exercised
2.07
+250.34%
0.59
+51.67%
0.39
-77.57%
1.73
Net Other Financing Charges
—
40.00
+8347.42%
-0.48
—
Changes In Cash
-79.58
-164.44%
123.50
+512.02%
20.18
+126.96%
-74.85
Beginning Cash Position
170.63
+262.02%
47.13
+74.86%
26.95
-73.52%
101.80
End Cash Position
91.05
-46.64%
170.63
+262.02%
47.13
+74.86%
26.95
Free Cash Flow
-370.18
-44.14%
-256.81
-90.97%
-134.47
-22.11%
-110.13
Amortization Of Securities
-5.30
-43.77%
-3.69
-577.39%
-0.54
+47.49%
-1.04
Change In Income Tax Payable
-8.56
0.00
—
—
Change In Tax Payable
-8.56
0.00
—
—
Common Stock Issuance
0.00
-100.00%
193.32
—
—
Issuance Of Capital Stock
0.00
-100.00%
451.78
+403.22%
89.78
-10.13%
99.89
Net Preferred Stock Issuance
0.00
-100.00%
258.46
+187.89%
89.78
-10.13%
99.89
Preferred Stock Issuance
0.00
-100.00%
258.46
+187.89%
89.78
-10.13%
99.89
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category